Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Golvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 10/20 | 0.91 |
| ▸ | KDR known ✓ | P35968 | 8/20 | 0.91 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.91 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.91 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.91 |
| ▸ | ABL1 | P00519 | 1/20 | 0.91 |
| ▸ | LCK | P06239 | 1/20 | 0.91 |
| ▸ | LYN | P07948 | 1/20 | 0.91 |
| ▸ | RET | P07949 | 1/20 | 0.91 |
| ▸ | HCK | P08631 | 1/20 | 0.91 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.91 |
| ▸ | BCR | P11274 | 1/20 | 0.91 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.91 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.91 |
| ▸ | FLT3 | P36888 | 1/20 | 0.91 |
| ▸ | ABL2 | P42684 | 1/20 | 0.91 |
| ▸ | FRK | P42685 | 1/20 | 0.91 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.91 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.91 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Golvatinib SCHEMBL93491 | 1.00 | MET (0.91) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL29678819 | 1.00 | MET (0.91) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1727298 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL30498607 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL30498608 | 0.95 | MET (1.00) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL4249254 | 0.95 | MET (0.99) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1727167 | 0.95 | MET (0.99) | METKDRNTRK1EPHB6RIPK2 | |
| SCHEMBL2250771 | 0.93 | MET (0.96) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1726888 | 0.93 | MET (0.85) | METKDRNTRK1EPHB6RIPK2 | |
| Golvatinib SCHEMBL1728754 | 0.93 | MET (0.92) | METKDRNTRK1EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | claimed |
| WO-2009142896-A3 | LANDSCAPE EDGING SYSTEM | WINK JOHN (US) | 2012-05-10 | — | — | WO | claimed |
| EP-2062886-B1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-30 | — | — | EP | claimed |
| US-7855290-B2 | N-[4-({2-[({4-[2-(Dimethylamino)ethyl]piperazin-1-yl}carbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; hepatocyte growth factor receptor (HGFR) inhibitors; antitumor, -carcinogenic, -metastasis agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-21 | — | — | US | claimed |
| EP-2062886-A1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | claimed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | claimed |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-25 | — | — | US | claimed |
| CN-121586709-A | Checkpoint kinase 1 (CHK 1) inhibitor crystal forms and uses thereof | 无界生物公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4688770-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITOR CRYSTALLINE FORM AND USES THEREOF | Boundless Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | BOUNDLESS BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4626433-A1 | CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF | Boundless Bio, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| EP-2586443-A1 | ANTITUMOR AGENT USING COMPOUNDS HAVING KINASE INHIBITORY EFFECT IN COMBINATION | Eisai R&D Management Co., Ltd. (JP) | 2013-05-01 | — | — | EP | disclosed |
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| WO-2009142896-A3 | LANDSCAPE EDGING SYSTEM | WINK JOHN (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2062886-B1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | EISAI R&D MAN CO LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| EP-2062886-A1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | HGF, MET, FLT1 | MET 2/4885KDR 9/4885NTRK1 206/4885 |
| US-20130123274-A1 | Antitumor Agent Using Compounds Having Kinase Inhibitory Effect in Combination | MAP3K8, MAP3K20, MAP3K7 | MET 685/4885KDR 531/4885NTRK1 654/4885 |
| US-12527790-B2 | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | CHEK1, RAD1, CHEK2 | MET 385/4885KDR 1081/4885NTRK1 1097/4885 |
| US-20080319188-A1 | Novel pyridine derivatives and pyrimidine derivatives (3) | HGF, MET, FLT4 | MET 2/4885KDR 8/4885NTRK1 157/4885 |
| US-20250367471-A1 | PERFUSION MODULATED TUMOR DOSE SCULPTING WITH SINGLE DOSE RADIOTHERAPY | TP53, CTPS1, TSG101 | MET 891/4885KDR 67/4885NTRK1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.